Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Sensitivity to TOP2 targeting chemotherapeutics is regulated by Oct1 and FILIP1L.

Lu H, Hallstrom TC.

PLoS One. 2012;7(8):e42921. doi: 10.1371/journal.pone.0042921.

2.

Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.

Raguz S, Adams C, Masrour N, Rasul S, Papoutsoglou P, Hu Y, Cazzanelli G, Zhou Y, Patel N, Coombes C, Yagüe E.

Biochem Pharmacol. 2013 Jan 15;85(2):186-96. doi: 10.1016/j.bcp.2012.10.020.

PMID:
23122841
3.

Downregulation of Filamin A interacting protein 1-like is associated with promoter methylation and induces an invasive phenotype in ovarian cancer.

Burton ER, Gaffar A, Lee SJ, Adeshuko F, Whitney KD, Chung JY, Hewitt SM, Huang GS, Goldberg GL, Libutti SK, Kwon M.

Mol Cancer Res. 2011 Aug;9(8):1126-38. doi: 10.1158/1541-7786.MCR-11-0162.

4.

Down-regulation of Filamin A interacting protein 1-like Is associated with promoter methylation and an invasive phenotype in breast, colon, lung and pancreatic cancers [corrected].

Kwon M, Lee SJ, Reddy S, Rybak Y, Adem A, Libutti SK.

PLoS One. 2013 Dec 5;8(12):e82620. doi: 10.1371/journal.pone.0082620. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/b2ee22c9-aa14-4c03-861c-b37f1a842bcd.

5.

Filamin A interacting protein 1-like inhibits WNT signaling and MMP expression to suppress cancer cell invasion and metastasis.

Kwon M, Lee SJ, Wang Y, Rybak Y, Luna A, Reddy S, Adem A, Beaty BT, Condeelis JS, Libutti SK.

Int J Cancer. 2014 Jul 1;135(1):48-60. doi: 10.1002/ijc.28662.

6.

Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.

Mamidipudi V, Shi T, Brady H, Surapaneni S, Chopra R, Aukerman SL, Heise C, Sung V.

Cancer Chemother Pharmacol. 2012 Apr;69(4):965-76. doi: 10.1007/s00280-011-1782-x.

PMID:
22120960
8.

NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.

Toyoda E, Kagaya S, Cowell IG, Kurosawa A, Kamoshita K, Nishikawa K, Iiizumi S, Koyama H, Austin CA, Adachi N.

J Biol Chem. 2008 Aug 29;283(35):23711-20. doi: 10.1074/jbc.M803936200.

9.

Introduction of gadd153 gene into gastric cancer cells can modulate sensitivity to anticancer agents in association with apoptosis.

Kim R, Ohi Y, Inoue H, Aogi K, Toge T.

Anticancer Res. 1999 May-Jun;19(3A):1779-83.

PMID:
10470115
10.

Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.

Namdar M, Perez G, Ngo L, Marks PA.

Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20003-8. doi: 10.1073/pnas.1013754107.

11.

Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.

Vavrova A, Jansova H, Mackova E, Machacek M, Haskova P, Tichotova L, Sterba M, Simunek T.

PLoS One. 2013 Oct 7;8(10):e76676. doi: 10.1371/journal.pone.0076676.

12.
13.

DNA damage signals induction of fas ligand in tumor cells.

Mo YY, Beck WT.

Mol Pharmacol. 1999 Feb;55(2):216-22.

14.

Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.

Malik M, Nitiss KC, Enriquez-Rios V, Nitiss JL.

Mol Cancer Ther. 2006 Jun;5(6):1405-14.

15.

Enhanced expression of the human vacuolar H+-ATPase c subunit gene (ATP6L) in response to anticancer agents.

Torigoe T, Izumi H, Ishiguchi H, Uramoto H, Murakami T, Ise T, Yoshida Y, Tanabe M, Nomoto M, Itoh H, Kohno K.

J Biol Chem. 2002 Sep 27;277(39):36534-43.

16.
17.

A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells.

Mallory JC, Crudden G, Oliva A, Saunders C, Stromberg A, Craven RJ.

Mol Pharmacol. 2005 Dec;68(6):1747-56.

18.

FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons.

Kachnic LA, Li L, Fournier L, Ferraiolo N, Dahm-Daphi J, Borgmann K, Willers H.

Cancer Lett. 2011 Jun 1;305(1):86-93. doi: 10.1016/j.canlet.2011.02.030.

PMID:
21414716
19.

Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer.

Wijdeven RH, Pang B, van der Zanden SY, Qiao X, Blomen V, Hoogstraat M, Lips EH, Janssen L, Wessels L, Brummelkamp TR, Neefjes J.

Cancer Res. 2015 Oct 1;75(19):4176-87. doi: 10.1158/0008-5472.CAN-15-0380.

20.

Atp-bound topoisomerase ii as a target for antitumor drugs.

Wang H, Mao Y, Zhou N, Hu T, Hsieh TS, Liu LF.

J Biol Chem. 2001 May 11;276(19):15990-5.

Items per page

Supplemental Content

Support Center